Velpanat – Generic Epclusa

Description

Velpanat is a breakthrough, pangenotypic, direct-acting antiviral (DAA) medication developed by Natco Pharma for the treatment of chronic Hepatitis C infection in adults. It contains two potent antiviral agents:

• Sofosbuvir (400 mg) – an NS5B polymerase inhibitor
• Velpatasvir (100 mg) – an NS5A inhibitor

Together, these drugs work synergistically to stop the hepatitis C virus from replicating and spreading in the body. Velpanat is especially effective because it can treat all genotypes of HCV (1 through 6), reducing the need for genotype-specific regimens.

Velpanat is typically administered once daily for 12 weeks, with or without Ribavirin based on the patient’s liver condition (e.g., decompensated cirrhosis).

Key Features:

• Contains Sofosbuvir 400 mg + Velpatasvir 100 mg
• Pangenotypic – treats genotypes 1 to 6 of HCV
• High cure rates (SVR >95%) after a 12-week treatment course
• No need for interferon or multiple pills
• Manufactured by Natco Pharma Ltd, a trusted name in Hepatitis C treatment
• WHO-prequalified and widely used in global treatment programs

Indications:

• Chronic Hepatitis C infection (genotypes 1–6)
• With or without compensated or decompensated cirrhosis
• Suitable for treatment-naïve or treatment-experienced adults

Dosage and Administration:

• Standard dose: One tablet once daily, with or without food
• Treatment duration: Typically 12 weeks; may be 24 weeks in patients with decompensated cirrhosis (often with Ribavirin)
• Follow your doctor’s complete instructions for optimal results

Precautions:

• Not recommended during pregnancy (especially if combined with Ribavirin)
• Use with caution in patients with severe liver or kidney disease
• May interact with other medications, especially antacids, anticonvulsants, and HIV drugs
• Inform your doctor of any pre-existing conditions, including co-infection with HIV or Hepatitis B

Storage Instructions:

• Store at room temperature below 30°C
• Keep away from moisture, heat, and direct sunlight
• Keep out of reach of children

FAQs – Velpanat

Q1: What is Velpanat used for?
A: Velpanat is used to treat chronic Hepatitis C virus infection in adults. It is effective against all genotypes (1–6), making it a universal treatment option.

Q2: How does Velpanat work?
A: Velpanat contains two antivirals—Sofosbuvir and Velpatasvir—that block specific proteins needed by the HCV virus to replicate. This helps clear the virus from the body over time.

Q3: Is Velpanat a cure for Hepatitis C?
A: Yes, in most cases. If taken as directed, Velpanat can achieve a Sustained Virologic Response (SVR) in over 95% of patients, which is considered a functional cure for HCV.

Q4: How long should I take Velpanat?
A: The standard treatment duration is 12 weeks. Some patients with more advanced liver disease may require 24 weeks, with or without Ribavirin, depending on medical evaluation.

Q5: What are the common side effects of Velpanat?
A: Common side effects include:

• Fatigue
• Headache
• Nausea
• Diarrhea
• Insomnia

Most side effects are mild. Notify your doctor if severe or unusual symptoms appear.

Q6: Can I take Velpanat with other medications?
A: Some drugs, such as antacids, rifampin, St. John’s Wort, and certain HIV medications, can interact with Velpanat. Always inform your doctor of all medications and supplements you are taking.

Q7: Can pregnant women take Velpanat?
A: Velpanat is not recommended during pregnancy, especially if combined with Ribavirin due to risks of birth defects. Effective contraception is advised during treatment.

Q8: Can Velpanat be used in patients with HIV-HCV co-infection?
A: Yes, Velpanat is safe and effective in patients co-infected with HIV and HCV, but careful monitoring and drug interaction assessment is required.

Q9: What happens if I miss a dose?
A: Take the missed dose as soon as you remember. If it’s almost time for your next dose, skip the missed one. Do not take a double dose.

Q10: Is a prescription required for Velpanat?
A: Yes, Velpanat is a prescription-only medication and must be used under the guidance of a healthcare professional.